<p>Halten näringsämnen i livsmedel varierar bland annat med tillagningsmetod, lagringstid och lagringsförhållanden, som exponering för ljus och syre. Oklarheter finns för mikrovågors inverkan på näringsämnen och framförallt på vitamin B₁₂. Eftersom många äldre drabbas av brist på vitamin B₁₂, är detta av intresse eftersom många hemmaboende äldre människor får hemleverans av färdiga matportioner som är avsedda att värmas, ofta i mikrovågsugn. Syftet med studien var att kunna ge en indikation på om uppvärmning genom mikrovågor påverkar halten vitamin B₁₂ i färdiga kylda måltider. Detta gjordes genom litteratursammanställning om vitamin B₁₂ och mikrovågar samt genom bioassay med <em>Lactobacillus delbrueckii</em>. Vitamin B₁₂ i ouppvärmd lax, lax värmd i mikrovågsugn samt lax värmd i konventionell ugn analyserades. Tillväxten av bakterier uppskattades genom mätning av turbiditet. Högst vitamin B₁₂-halt sågs i mikrovågsvärmd lax, därefter ouppvärmd lax och ugnsvärmd lax. Statistiskt signifikanta skillnader sågs för analyserade vitamin B₁₂-halter mellan ouppvärmt- och ugnsvärmt prov respektive mellan mikrovågsvärmt- och ugnsvärmt prov. De varierande vitaminhalterna kan bero på metodfel, otillräcklig vitaminextraktion eller att bakterierna inte konsumerat allt tillgängligt vitamin vid turbiditetsmätning. Slutsatsen av studien är att halten vitamin B₁₂ i livsmedel inte verkar påverkas negativt av mikrovågor, däremot finns tendenser att halten minskar beroende av temperatur och tillagningstid.</p>

No description available.

Bei Dialysepatienten sind vermehrte Genomschäden bekannt, sie unterliegen auch einer erhöhten Karzinominzidenz. Erhöhte Genomschäden können in vivo durch die Substitution von Folsäure reduziert werden, unter Gabe von Vitamin B12 sinkt die Empfindlichkeit gegenüber genotoxischen Agentien. 27 Dialysepatienten nahmen an dieser Studie teil. Die 9 Patienten der Substitutions-gruppe Folsäure erhielten dreimal wöchentlich 15 mg Folsäure intravenös, den 10 Patienten der Substitutionsgruppe Folsäure + Vitamin B12 wurde zusätzlich einmal wöchentlich 1000 µg Vitamin B12 intravenös verabreicht. 8 Dialysepatienten und 7 nicht dialysepflichtige Probanden dienten als Kontrolle. Zu drei Zeitpunkten vor und drei Zeitpunkten nach Substitutionsbeginn wurden die Mikrokernfrequenzen in peripheren, doppelkernigen Lymphozyten bestimmt. Mikro-kerne dienen als Marker für Genomschäden, die Methode ist gut erprobt und es ist ein Zusammenhang zwischen erhöhten Mikrokernfrequenzen und einer prospektiv erhöhten Karzinominzidenz beschrieben. Weiterhin wurden die Homocystein-Plasmaspiegel vor und nach Substitutionsbeginn gemessen. Homocystein zählt zu den Urämietoxinen, in vitro steigt bei erhöhten Homocysteinwerten dosisabhängig der Genomschaden in Form von Mikrokernen an. Vor Substitutionsbeginn wiesen die Dialysepatienten um ein mehrfaches gegenüber den Referenzwerten erhöhte Mikrokernfrequenzen auf, wobei die Mikrokernfrequenzen der Frauen deutlich über denen der Männer lagen. Mit zunehmender Dialysedauer kam es zu einer Reduktion der Mikrokernfrequenz, wobei diese immer noch gegenüber den Referenzwerten erhöht blieb. Unter Gabe von Folsäure + Vitamin B12 kam es zu einem signifikant stärkeren Rückgang der Mikrokernfrequenz als unter alleiniger Folsäuregabe. Dieser Rückgang unter Vitaminsubstitution nahm mit zunehmendem Dialysealter zunächst zu, bei einer Dialysedauer von länger als 10 Jahren nahm er wieder ab. Die Homocysteinspiegel waren vor Substitutionsbeginn deutlich erhöht. Unter kombinierter Gabe von Folsäure und Vitamin B12 kam es zu einer signifikanten Reduktion der Homocysteinwerte, so dass diese sogar unterhalb der im Normbereich liegenden Homocysteinwerte der nicht dialysepflichtigen Kontrollgruppe lagen. Ob die in der Studie vielversprechende kombinierte Substitution von Folsäure und Vitamin B12 tatsächlich das Krebsrisiko von Dialysepatienten beeinflussen kann, wird nur durch prospektive Langzeitstudien zu klären sein. Ebenfalls werden weitere Studien nötig sein, um die optimale Dosis, welche möglicherweise in Abhängigkeit von Alter, Geschlecht, Dialysedauer und Grunderkrankung variieren kann, zu ermitteln. Weitere Vorteile einer therapeutischen Gabe von Folsäure und Vitamin B12 liegen sicherlich einerseits in den vergleichsweise geringen Kosten und andererseits in der guten Verträglichkeit, welche für die Compliance der Patienten von großer Bedeutung ist. / A reduction of genomic damage in PBL can be achieved in dialysis patients by supplementation with folic acid and vitamin b12. This may be mediated by a combination of homocsteine reduction and enhancement of plasma antioxidant capacity.

Mycobacterium tuberculosis (MTB) encodes three enzymes that are dependent on vitamin B12–derived cofactors for activity, including a B12-dependent methionine synthase (MetH). Previously, work in the Molecular Mycobacteriology Research Unit (MMRU) demonstrated vitamin B12 auxotrophy in a mutant strain disrupted in the alternative, B12-independent methionine synthase, MetE. This observation established the ability of MTB to transport corrinoids despite the absence of an identifiable B12-specific transporter. In addition, it suggested that MTB does not synthesize vitamin B12 in vitro. Notably, bioinformatic analyses identified PPE2 as the only B12-related transport candidate in MTB, though as a putative B12-regulated cobalt transporter. PPE2 is unusual in possessing directly upstream of its predicted start codon one of only two B12-dependent riboswitches in the MTB genome, and it lies in a putative operon with B12 biosynthetic genes, cobU and cobQ1. In this study, the possibility that PPE2 functions in the transport of vitamin B12 or cobalt was investigated. Transcriptional and phenotypic data suggested that PPE2 was not involved in B12 transport. Instead, it was shown that cobalt can supplement the growth of an MTB metE mutant in liquid medium, strongly supporting the ability of MTB to synthesize B12 de novo. Moreover, the ability to utilise exogenous cobalt was dependent on functional PPE2, thereby establishing a role for a PPE-family member in cobalt assimilation in MTB. Vitamin B12 comprises a central corrin ring co-ordinated to 5,6-dimethylbenzimidazole (DMB) as α-axial ligand. Substituting DMB with adenine yields the alternate form, pseudo-B12. The ability of mycobacteria to utilize pseudo-B12 precursors (cobinamide and adenine) to support full function of B12-dependent metabolic pathways was evaluated. Although the pseudo-B12 precursors appeared to complement chemically the mycobacterial B12 auxotrophs, growth of the mutants on cobinamide alone complicated this interpretation. To address this limitation, DMB synthesis was targeted by disrupting the MTB bluB homologue, Rv0306. Neither site-directed mutagenesis of key Rv0306 residues, nor full-gene deletion was sufficient to eliminate growth on cobinamide. Instead, this observation highlights the need to establish biochemically the nature of the active B12 form synthesized and utilized by MTB under different conditions. In combination, the results presented here support the inferred flexibility of vitamin B12 biosynthesis in MTB, and reinforce the potential role of B12-dependent metabolism in mycobacterial pathogenesis.

No description available.

Thesis (Ph. D.)--University of California, San Diego, 1983. / Vita. Includes bibliographical references (leaves 133-138).

Graduation date: 1992

Human skin fibroblasts derived from patients with all 7 known inborn errors of vitamin B$ sb{12}$ metabolism have been studied for functional integrity of methylmalonyl CoA mutase and methionine synthase. Cocultivation of cblC and cblF fibroblasts in the absence of polyethylene glycol resulted in a twofold increase over the expected in both ($ sp{14}$C) propionate and ($ sp{14}$C) methyltetrahydrofolate incorporation into acid-precipitable material, suggesting that metabolic cooperation between cells occurs. CblD fibroblasts, which are biochemically similar to cblC cells (Goodman et al, 1970; Willard et al, 1977), do not cooperate metabolically when mixed with cblF cells. Partial correction in phenotype was seen in mixtures of cblD and cblG cells, but not cblC and cblG cells. These observations lend further support for the division of cblC and cblD disease into two discrete complementation classes. Cocultivation of cblF fibroblasts with both cblE and cblG cells also resulted in partial correction in phenotype. / ($ sp{14}$C) Propionate incorporation in both cblC and cblF cells exposed to conditioned medium from control cells was increased more than twofold. ($ sp{14}$C) methyltetrahydrofolate incorporation in cblC cells exposed to conditioned medium from cblF cells was increased twofold. This suggests the presence of a diffusible factor correcting the defect in the mutant cell lines.

Methylmalonic aciduria (MMA) is an autosomal recessive metabolic disorder with an incidence of 1 in 48,000, which may be due to a defect in the mitochondrial homodimeric enzyme methylmalonyl CoA mutase (mut MMA). mut MMA is subdivided into $mut sp circ$ and $mut sp-$ subclasses on the basis of complementation analysis; $mut sp circ$ cell lines have very low incorporation of ($ sp{14}$C) from propionate into acid precipitable material while incorporation in $mut sp-$ cells is increased when cells are incubated in cobalamin. Intragenic complementation was first observed with WG 1130, a $mut sp circ$ fibroblast line with a homozygous R93H mutation, that is capable of complementing MCM activity when fused with some $mut sp circ$ and some $mut sp-$ cells (1). Extensive intragenic complementation in mut MMA was subsequently observed. Fibroblasts cultured from thirteen unrelated patients (6 $mut sp-$, 7 $mut sp circ$) were fused in all possible pairwise combination and MCM activity was assayed in the heterokaryons by measuring the incorporation of ($ sp{14}$C) from propionate into acid precipitable material. Intragenic complementation, indicated by stimulation of ($ sp{14}$C) -propionate incorporation following cell fusion with polyethylene glycol, was observed in fusions involving twelve of the thirteen strains. Of these thirteen strains, mutations have been identified in six; four have a homozygous mutation (WG 1130 (R93H), WG 1511 (H678R), WG 1610 (G717V), WG 1609 (G630E)), and two cell lines are compound heterozygous (WG 1681 (G623R and G703R), WG 1607 (W105R and A377E)); the remainders are yet to be determined. These intragenic complementations will provide information for grouping the mutations in defined domains in order to correlate structure and function of MCM.

Methylmalonic aciduria is an autosomal recessive metabolic disorder, which may be due to a defect in the methylmalonyl CoA mutase (MCM) apoenzyme. The mut$ sp circ$ mutation is characterized by undetectable enzyme activity in cell extracts, and by the low incorporation of ($ sp{14}$C) propionate in the presence of hydroxocobalamin in culture. A mut$ sp circ$ fibroblast cell line, WG 1681, from an African-American male infant was shown to complement another mut$ sp circ$ cell line, WG 1130. Subsequent cloning and sequencing of cDNA from WG 1681 identified two previously described homozygous polymorphisms: H532R and V671I(1). In addition, compound heterozygosity was observed for two novel changes at highly conserved sites: G623R and G703R. Hybridization of allele specific oligonucleotides to PCR amplified MCM exons from WG 1681 and family members identified a clinically normal mother, sister and half-brother as carriers of the G703R change in cis with both polymorphisms. The putative father was not identified as a carrier of the G623R change. transfection of each change, singly and in cis with both polymorphisms, into GM1673 cells demonstrated a lack of stimulation of ($ sp{14}$C) propionate uptake in the absence and presence of OH-Cbl, in comparison to controls. Co-transfection of each separate mutation with the previously identified R93H mutation of WG 1130 (2) stimulated propionate uptake. These results indicate that G623R and G703R are novel mutations responsible for deficient MCM activity and the mut$ sp circ$ phenotype in WG 1681, and both mutations are independently capable of complementing the R93H mutation of WG 1130.